Category: advocacy

Tell AAA To Stop Lying About Legalization

Over the first six months of 2017, the American Automobile Association (aka AAA) has been spreading misinformation and propaganda in a lobbying effort to defeat marijuana legalization legislative efforts in Connecticut, Delaware, Maryland, and other states.

Register for the 2017 NORML Conference

NORML’s 2017 Conference at the Capitol Hilton in Washington, DC and Congressional Lobby Day at the United States Capitol is scheduled for September 10th-12th. Hundreds of marijuana consumers, activists, patients and business owners are expected to attend a day-long training and informational conference on Monday and re-convene on The Hill Tuesday to personally lobby their elected members of the House of Representatives and Senate.

Two New Virginia Laws Foreshadow Larger Cannabis Policy Changes

A common cliché for overcoming a difficult obstacle asks, “how do you eat an elephant?” The answer is, “one bite at a time.” In Virginia politics, the tough question facing cannabis policy reform advocates is, “how do you change the minds of political Elephants?” The answer is, “one law at a time.” Although progress in cannabis reform has been slow in Virginia, two recent bills signed by Governor Terry McAuliffe are significant signs that change is coming, and quicker than ever before.

Setting The Record Straight

One of NORML’s primary missions is to move public opinion sufficiently to legalize the responsible use of marijuana by adults. One of the ways we successfully achieve this goal is by debunking marijuana myths and half-truths via the publication of timely op-eds in online and print media. Since the mainstream media seldom casts a critical eye toward many of the more over-the-top claims about cannabis, we take it upon ourselves to set the record straight.

Will the House of Representatives Let Jeff Sessions Shut Down Medical Marijuana?

This week, the House Appropriations Committee released its 2018 Commerce, Justice, Science (CJS) Appropriations bill, which determines the funding levels for numerous federal agencies, including the Department of Justice. Predictably, the bill does not include language — known as the Rohrabacher-Blumenauer amendment — limiting the Justice Department from taking action against state-sanctioned medical cannabis producers, retailers, or consumers.